Globenewswire·2026-03-13 20:56Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Soleno Therapeutics, Inc. common stock during the specified Class Period, indicating potential legal issues related to the company's disclosures and clinical trial results [1][5]. Group 1: Class Action Details - The class action lawsuit is for investors who purchased Soleno common stock between March 26, 2025, and November 4, 2025, and they may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2][3]. - Investors wishing to serve as lead plaintiff must file a motion with the Court by May 5, 2026 [1][3]. Group 2: Allegations Against Soleno Therapeutics - The lawsuit alleges that Soleno made false or misleading statements regarding the safety of its Phase 3 clinical trial program for diazoxide choline extended-release tablets (DCCR), particularly concerning significant safety concerns related to excess fluid retention [5]. - It is claimed that the administration of DCCR posed materially greater safety risks than disclosed, affecting its commercial viability and leading to potential adverse events post-launch [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone, and has received recognition from various legal authorities [4].